Cargando…
Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747716/ http://dx.doi.org/10.1038/sj.bjc.6602101 |
_version_ | 1782172121676382208 |
---|---|
author | Ohwada, S Morishita, Y |
author_facet | Ohwada, S Morishita, Y |
author_sort | Ohwada, S |
collection | PubMed |
description | |
format | Text |
id | pubmed-2747716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27477162009-09-21 Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer Ohwada, S Morishita, Y Br J Cancer Letter to the Editor Nature Publishing Group 2004-09-13 2004-08-10 /pmc/articles/PMC2747716/ http://dx.doi.org/10.1038/sj.bjc.6602101 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Letter to the Editor Ohwada, S Morishita, Y Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer |
title | Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer |
title_full | Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer |
title_fullStr | Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer |
title_full_unstemmed | Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer |
title_short | Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer |
title_sort | reply: adjuvant immunochemotherapy with oral tegafur/uracil plus psk in patients with stage ii or iii colorectal cancer |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747716/ http://dx.doi.org/10.1038/sj.bjc.6602101 |
work_keys_str_mv | AT ohwadas replyadjuvantimmunochemotherapywithoraltegafururacilpluspskinpatientswithstageiioriiicolorectalcancer AT morishitay replyadjuvantimmunochemotherapywithoraltegafururacilpluspskinpatientswithstageiioriiicolorectalcancer |